Drugs / 4-ISOTHIOUREIDOBUTYRONITRILE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01664000 | Oct 2012 → Jan 2016 | cancer | Cellceutix Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03042702 | Feb → Nov 2017 | ovarian cancer | Innovation Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4-ISOTHIOUREIDOBUTYRONITRILE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297540 ↗ |
| Known as | Kevetrin | “Kevetrin (thioureidobutyronitrile)” NCT01664000 ↗ |
| Known as | NSC-525990 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297540 ↗ |
| Known as | Thioureidobutyronitrile | “Cellceutix has developed Kevetrin (thioureidobutyronitrile), belonging to an anti-proliferative p53 activator pharmacological class, for the treatment of cancer.” NCT03042702 ↗ |
| Action | Activate | “Kevetrin activates p53” NCT01664000 ↗ |
| Modality | Small molecule | — CHEMBL4297540 ↗ |
| Route | Intravenous | “Administered Intravenously” NCT01664000 ↗ |
| Target | TP53 | “Kevetrin activates p53” NCT01664000 ↗ |